Cencora, Inc. $COR Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp cut its holdings in Cencora, Inc. (NYSE:COR) by 2.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 281,939 shares of the company’s stock after selling 6,198 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Cencora were worth $84,539,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Voleon Capital Management LP acquired a new stake in Cencora during the 1st quarter valued at $3,111,000. Focus Partners Wealth lifted its position in shares of Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after acquiring an additional 1,171 shares in the last quarter. Martin Capital Partners LLC lifted its position in shares of Cencora by 205.2% in the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after acquiring an additional 2,544 shares in the last quarter. Fiduciary Alliance LLC acquired a new stake in shares of Cencora during the second quarter valued at $262,000. Finally, Acadian Asset Management LLC increased its position in Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after purchasing an additional 232,539 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 41,544 shares of company stock valued at $12,230,941. Corporate insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on COR. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Robert W. Baird upped their price objective on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company lifted their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, TD Cowen increased their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Stock Up 0.2%

Shares of NYSE COR opened at $365.26 on Wednesday. The stock has a market capitalization of $70.82 billion, a PE ratio of 37.58, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The firm has a fifty day moving average of $317.14 and a 200-day moving average of $300.68. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $366.17.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter last year, the firm earned $3.34 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.